Literature DB >> 1524915

Prolonged chemotherapy for localised squamous carcinoma of the oesophagus.

J A Ajani1, B Ryan, T A Rich, M McMurtrey, J A Roth, L DeCaro, B Levin, C Mountain.   

Abstract

We evaluated the feasibility of six courses of chemotherapy in 34 consecutive patients with localised squamous cell carcinoma of the oesophagus. All 32 evaluable patients first received at least two courses of chemotherapy. There were 18 patients with resectable carcinomas who underwent surgery and 14 patients with unresectable carcinomas who received definitive chemoradiotherapy. After two courses of 5-fluorouracil and cisplatin 21 (66%) of 32 patients had either a complete or major response. A median of five courses (range, 1-6 courses) was administered. 17 out of 18 (94%) patients with resectable carcinoma had a 'curative' resection (negative proximal, distal, and radial margins by histopathology in an en-block resection specimen) and 2 patients had a complete pathological response. The median survival duration of all patients was 28 months (range, 2-46+ months). The median survival duration of 14 patients with unresectable carcinoma was 23 months (range, 8-36+ months), and the median survival duration of 18 patients with resectable carcinoma has not been reached at a median follow-up of 24+ months (range, 10+ to 46+ months). No deaths occurred because of chemotherapy or chemoradiation therapy. Our data suggest that prolonged chemotherapy is feasible in patients with locoregional squamous carcinoma of the oesophagus. An ongoing controlled trial will determine the contribution of chemotherapy to patients' survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524915     DOI: 10.1016/0959-8049(92)90140-w

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.

Authors:  Y Hosoya; H Shibusawa; H Nagai; I Ueno; K Sakuma; T Nagashima; N Kobayashi; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

3.  Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.

Authors:  H Sekiguchi; S Akiyama; M Fujiwara; H Nakamura; K Kondo; Y Kasai; K Ito; J Sakamoto; H Takagi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.

Authors:  B L Brücher; W Weber; M Bauer; U Fink; N Avril; H J Stein; M Werner; F Zimmerman; J R Siewert; M Schwaiger
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

5.  First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.

Authors:  E Ancona; A Ruol; C Castoro; V Chiarion-Sileni; S Merigliano; S Santi; L Bonavina; A Peracchia
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

6.  Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.

Authors:  Davide Adriano Santeufemia; Gianfranca Piredda; Giovanni Maria Fadda; Paolo Cossu Rocca; Salvatore Costantino; Giovanni Sanna; Maria Giuseppa Sarobba; Maria Antonietta Pinna; Carlo Putzu; Antonio Farris
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

7.  Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer.

Authors:  Tadasuke Hashiguchi; Motomi Nasu; Takashi Hashimoto; Tetsuji Kuniyasu; Hirohumi Inoue; Noritaka Sakai; Kazutomo Ouchi; Takayuki Amano; Fuyumi Isayama; Natsumi Tomita; Yoshimi Iwanuma; Masahiko Tsurumaru; Yoshiaki Kajiyama
Journal:  Mol Clin Oncol       Date:  2014-06-19

8.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03

9.  Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.

Authors:  M Yamasaki; T Makino; T Masuzawa; Y Kurokawa; H Miyata; S Takiguchi; K Nakajima; Y Fujiwara; N Matsuura; M Mori; Y Doki
Journal:  Br J Cancer       Date:  2011-01-04       Impact factor: 7.640

10.  Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.

Authors:  S Petrasch; A Welt; A Reinacher; U Graeven; M König; W Schmiegel
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.